Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
Fontaine
Camille
C
Guiard-Schmid
Jean-Baptiste
JB
Slama
Laurence
L
Essid
Aben
A
Lukiana
Tuna
T
Rondeau
Eric
E
Pialoux
Gilles
G
D019380:Anti-HIV Agents / Q000009:adverse effects*; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D058607:Fibric Acids; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced*; D000099227:Abacavir
D019380:Anti-HIV Agents; D002995:Clofibric Acid; D015224:Dideoxynucleosides; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D000099227:Abacavir; C019304:ciprofibrate